Good point. But, I believe most people are going with what they have heard in CC's which has been all partnership and not a buyout. However, I do believe it just might be their strategy. They don't have to walk around talking about a sale to do a sale. In fact, with all of their public talk about a partnership, a potential buyer might up the sales price to overcome their ideas of partnering. Of course, who really knows for sure?
But this company is unlike any he's had before. It is named after himself and I see it as his legacy. He may sell it at some point in time but only if it will continue to operate under the same name and more or less autonomous as part of a larger brand. The partner could well be the eventual buyer, but first it will be partnership I think.
If he is not going to partner and sell, then it better be for north of $15-20 a share...afrezza is a big part but so is the inhaler that has applications across many other drug therapies. Long 24k shares